These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 16926600

  • 41. WOFIE stimulates regulatory T cells: a 2-year follow-up of renal transplant recipients.
    Dresske B, Haendschke F, Lenz P, Ungefroren H, Jenisch S, Exner B, El Mokhtari NE, Lu T, Zavazava N, Faendrich F.
    Transplantation; 2006 Jun 15; 81(11):1549-57. PubMed ID: 16770244
    [Abstract] [Full Text] [Related]

  • 42. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A, Noble A.
    J Leukoc Biol; 2007 Nov 15; 82(5):1053-61. PubMed ID: 17684039
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. The role of Foxp3+ regulatory T cells in kidney transplantation.
    Karczewski M, Karczewski J, Kostrzewa A, Wiktorowicz K, Glyda M.
    Transplant Proc; 2009 Jun 15; 41(5):1527-9. PubMed ID: 19545671
    [Abstract] [Full Text] [Related]

  • 45. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy.
    Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G.
    Transplantation; 2008 Jan 15; 85(1):125-34. PubMed ID: 18192922
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin.
    Lange CM, Tran TY, Farnik H, Jungblut S, Born T, Wagner TO, Hirche TO.
    Transpl Int; 2010 Mar 01; 23(3):266-76. PubMed ID: 19804585
    [Abstract] [Full Text] [Related]

  • 48. T cell receptor beta chain (TCR-Vbeta) repertoire of circulating CD4(+) CD25(-), CD4(+) CD25(low) and CD4(+) CD25(high) T cells in patients with long-term renal allograft survival.
    Velásquez SY, Arias LF, García LF, Alvarez CM.
    Transpl Int; 2010 Jan 01; 23(1):54-63. PubMed ID: 19694999
    [Abstract] [Full Text] [Related]

  • 49. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan 01; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 50. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 01; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 51. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS, Ramicone E, Fong TL.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):513-20. PubMed ID: 16441472
    [Abstract] [Full Text] [Related]

  • 52. T(H)17 versus Treg cells in renal transplant candidates: effect of a previous transplant.
    San Segundo D, López-Hoyos M, Fernández-Fresnedo G, Benito MJ, Ruiz JC, Benito A, Rodrigo E, Arias M.
    Transplant Proc; 2008 Nov 15; 40(9):2885-8. PubMed ID: 19010136
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
    Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G.
    J Am Soc Nephrol; 2007 Mar 15; 18(3):1007-18. PubMed ID: 17287424
    [Abstract] [Full Text] [Related]

  • 55. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C, Dousdampanis P, Sakellaraki P, Rodi M, Georgakopoulos T, Vlachojannis JG, Mouzaki A.
    Am J Nephrol; 2010 Mar 15; 32(1):1-9. PubMed ID: 20484893
    [Abstract] [Full Text] [Related]

  • 56. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct 15; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 57. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ.
    Transplantation; 2007 Mar 27; 83(6):722-6. PubMed ID: 17414704
    [Abstract] [Full Text] [Related]

  • 58. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
    Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, Conesa J, Cotorruelo JG, Gómez-Alamillo C, Calvo N, Barrientos A, Arias M.
    Transplant Proc; 2006 Oct 27; 38(8):2424-6. PubMed ID: 17097956
    [Abstract] [Full Text] [Related]

  • 59. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients.
    Akl A, Jones ND, Rogers N, Bakr MA, Mostafa A, El Shehawy el M, Ghoneim MA, Wood KJ.
    Transpl Int; 2008 Jan 27; 21(1):65-73. PubMed ID: 17887959
    [Abstract] [Full Text] [Related]

  • 60. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
    González-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Martín-Durán R.
    J Heart Lung Transplant; 2011 May 27; 30(5):552-7. PubMed ID: 21212001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.